Sales of another leukemia drug, Venclexta, have shown strong trend in the first half of 2019 with sales more than doubling year over year on the back of label expansion in additional indications. In May, the drug was approved in combination with Roche's RHHBY Gazyva as first-line treatment for CLL patients, which might have brought additional sales in third-quarter. The Zacks Consensus Estimate for the drug is pegged at $208 million